These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 33592563)
21. Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges. Rizzo A; Federico AD; Ricci AD; Frega G; Palloni A; Pagani R; Tavolari S; Marco MD; Brandi G Cancer Control; 2020; 27(1):1073274820983013. PubMed ID: 33356500 [TBL] [Abstract][Full Text] [Related]
22. Capecitabine Extends Survival for Biliary Tract Cancer. Cancer Discov; 2017 Jul; 7(7):OF1. PubMed ID: 28572460 [TBL] [Abstract][Full Text] [Related]
23. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. Bridgewater J; Fletcher P; Palmer DH; Malik HZ; Prasad R; Mirza D; Anthony A; Corrie P; Falk S; Finch-Jones M; Wasan H; Ross P; Wall L; Wadsley J; Evans TR; Stocken D; Stubbs C; Praseedom R; Ma YT; Davidson B; Neoptolemos J; Iveson T; Cunningham D; Garden OJ; Valle JW; Primrose J; J Clin Oncol; 2022 Jun; 40(18):2048-2057. PubMed ID: 35316080 [TBL] [Abstract][Full Text] [Related]
24. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study. Siebenhüner AR; Seifert H; Bachmann H; Seifert B; Winder T; Feilchenfeldt J; Breitenstein S; Clavien PA; Stupp R; Knuth A; Pestalozzi B; Samaras P BMC Cancer; 2018 Jan; 18(1):72. PubMed ID: 29325521 [TBL] [Abstract][Full Text] [Related]
25. Adjuvant chemotherapy for resectable biliary tract cancer: current status and future direction. Konishi M J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):301-5. PubMed ID: 22262202 [TBL] [Abstract][Full Text] [Related]
26. First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!". Rizzo A; Brandi G Cancer Treat Res Commun; 2021; 27():100335. PubMed ID: 33592561 [TBL] [Abstract][Full Text] [Related]
28. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study. Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981 [TBL] [Abstract][Full Text] [Related]
29. A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer. Iyer RV; Pokuri VK; Groman A; Ma WW; Malhotra U; Iancu DM; Grande C; Saab TB Am J Clin Oncol; 2018 Jul; 41(7):649-655. PubMed ID: 27849649 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of gemcitabine monotherapy for patients with advanced biliary tract cancer. Yokoyama T; Yoshida H; Makino H; Maruyama H; Suzuki S; Matsutani T; Matsushita A; Hirakata A; Sasajima K; Uchida E J Nippon Med Sch; 2012; 79(3):204-12. PubMed ID: 22791122 [TBL] [Abstract][Full Text] [Related]
32. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study. Kim MJ; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ BMC Cancer; 2008 Dec; 8():374. PubMed ID: 19091129 [TBL] [Abstract][Full Text] [Related]
33. Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives. Filippi R; Lombardi P; Quarà V; Fenocchio E; Aimar G; Milanesio M; Leone F; Aglietta M Expert Opin Pharmacother; 2019 Dec; 20(17):2121-2137. PubMed ID: 31550186 [No Abstract] [Full Text] [Related]
34. Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer. Nakachi K; Konishi M; Ikeda M; Shimada K; Okusaka T; Saiura A; Ishii H; Sugiyama M; Furuse J; Sakamoto H; Shimamura T; Ohta T Int J Clin Oncol; 2018 Oct; 23(5):894-899. PubMed ID: 29705976 [TBL] [Abstract][Full Text] [Related]
35. Current progress in systemic therapy for biliary tract cancers. Sutherland M; Ahmed O; Zaidi A; Ahmed S J Hepatobiliary Pancreat Sci; 2022 Oct; 29(10):1094-1107. PubMed ID: 33735541 [TBL] [Abstract][Full Text] [Related]
36. Current progress in perioperative chemotherapy for biliary tract cancer. Ioka T; Shindo Y; Ueno M; Nagano H Ann Gastroenterol Surg; 2023 Jul; 7(4):565-571. PubMed ID: 37416744 [TBL] [Abstract][Full Text] [Related]
37. Systematic review with network meta-analysis: adjuvant therapy for resected biliary tract cancer. Zhu GQ; Shi KQ; You J; Zou H; Lin YQ; Wang LR; Braddock M; Chen YP; Zheng MH Aliment Pharmacol Ther; 2014 Oct; 40(7):759-70. PubMed ID: 25099956 [TBL] [Abstract][Full Text] [Related]
38. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731 [TBL] [Abstract][Full Text] [Related]
39. Surgical treatment and adjuvant chemotherapy for patients with biliary tract cancer: single institution experience of 100 patients. Harada N; Shirabe K; Yoshizumi T; Ikegami T; Uchiyama H; Soejima Y; Yamashita Y; Saeki H; Oki E; Kawanaka H; Morita M; Ikeda T; Matsuura H; Okadome K; Maehara Y Fukuoka Igaku Zasshi; 2013 Dec; 104(12):539-48. PubMed ID: 24693682 [TBL] [Abstract][Full Text] [Related]